ABR

By Targets:	Apoptosis (4) HDAC (2) Isotope-Labeled Compounds (4) NF-κB (4) SARS-CoV (3) Small Interfering RNA (siRNA) (1) TNF Receptor (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (1) Inflammation/Immunology (9) Metabolic Disease (3) Neurological Disease (1)
Oligonucleotides:	Pre-designed siRNA Sets (1) siRNAs (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-141537

ABR-238901 4 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial infarction (MI) research .

HY-100442

Paquinimod Maximum Cited Publications 16 Publications Verification ABR-215757; ABR 25757	SARS-CoV	Metabolic Disease Inflammation/Immunology
Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-13010

Laquinimod 2 Publications Verification ABR-215062	NF-κB Apoptosis	Inflammation/Immunology
Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has?the?potential?for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases?research .

HY-13010S

Laquinimod-d5 ABR-215062-d₅	Isotope-Labeled Compounds Apoptosis NF-κB	Inflammation/Immunology
Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

HY-13743

Roquinimex Linomide; FCF89; ABR212616	TNF Receptor	Inflammation/Immunology
Roquinimex (Linomide; PNU212616; ABR212616) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha.

HY-10528S

Tasquinimod-d3 ABR-215050-d₃	HDAC Isotope-Labeled Compounds	Cancer
Tasquinimod-d3 (ABR-215050-d3) is the deuterium labeled Tasquinimod (HY-10528). Tasquinimod is an oral antiangiogenic agent, which plays an important role in castration-resistant prostate cancer. Tasquinimod binds to the regulatory Zn ²⁺ binding domain of HDAC4 with K_d of 10-30 nM. Tasquinimod also is a S100A9 inhibitor .

HY-100442S1

Paquinimod-d5-1 ABR-215757-d₅-1; ABR 25757-d₅-1	SARS-CoV Isotope-Labeled Compounds	Metabolic Disease Inflammation/Immunology
Paquinimod-d5-1 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-RS00110

ABR Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ABR Human Pre-designed siRNA Set A contains three designed siRNAs for ABR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ABR Human Pre-designed siRNA Set A ABR Human Pre-designed siRNA Set A

HY-W062904

Laquinimod sodium ABR-215062 sodium	NF-κB Apoptosis	Neurological Disease Inflammation/Immunology
Laquinimod (ABR-215062) sodium, an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod sodium reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod sodium has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

HY-100442S

Paquinimod-d5 ABR-215757-d₅; ABR 25757-d₅	SARS-CoV Isotope-Labeled Compounds	Metabolic Disease
Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-10528

Tasquinimod 5+ Cited Publications ABR-215050	HDAC	Cancer
Tasquinimod is an oral antiangiogenic agent, which has the potential for castration-resistant prostate cancer treatment. Tasquinimod binds to the regulatory Zn ²⁺ binding domain of HDAC4 with K_d of 10-30 nM. Tasquinimod also is a S100A9 inhibitor .

HY-13010R

Laquinimod (Standard)	NF-κB Apoptosis	Inflammation/Immunology
Laquinimod (Standard) is the analytical standard of Laquinimod. This product is intended for research and analytical applications. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

Cat. No.	Product Name	Target	Research Area

HY-P99436

Anatumomab mafenatox ABR-214936	Inhibitory Antibodies	Cardiovascular Disease Inflammation/Immunology Cancer
Anatumomab mafenatox (ABR-214936) is a 73 KDa recombinant protein to recognize the tumor-associated antigen 5T4, which is widely expressing in malignancy. Anatumomab mafenatox is between a modified form of SEA and a murine Fab. The main side effects of Anatumomab mafenatox are reported to include fever, low blood pressure, pain, nausea and drowsiness .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P99436

Anatumomab mafenatox ABR-214936	Cardiovascular Disease Classification of Application Fields Disease Research Fields	Others
Anatumomab mafenatox (ABR-214936) is a 73 KDa recombinant protein to recognize the tumor-associated antigen 5T4, which is widely expressing in malignancy. Anatumomab mafenatox is between a modified form of SEA and a murine Fab. The main side effects of Anatumomab mafenatox are reported to include fever, low blood pressure, pain, nausea and drowsiness .

Species:	Virus (4)
Tag:	His (4)
Source:	HEK293 (3) Sf9 insect cells (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P73794

	*NA/Neuraminidase Protein, H1N1 (ABR28848, HEK293, His)* NA; Neuraminidase; NA/Neuraminidase Protein, H1N1 (A/Auckland/606/2001, HEK293, His)	Virus	HEK293
	NA/Neuraminidase Protein is a receptor-destroying enzyme that cleaves terminal sialic acids from cellular receptors, potentially facilitating viral invasion of the upper airways by targeting sialic acid moieties on airway epithelial cell mucin. NA plays a pivotal role in viral propagation by catalyzing the removal of terminal sialic acid residues from both viral and cellular glycoconjugates. Moreover, the sialidase activity in late endosome/lysosome traffic appears to enhance virus replication. NA/Neuraminidase Protein, H1N1 (ABR28848, HEK293, His) is the recombinant Virus-derived NA/Neuraminidase protein, expressed by HEK293 , with N-His labeled tag. The total length of NA/Neuraminidase Protein, H1N1 (ABR28848, HEK293, His) is 435 a.a., with molecular weight of ~50.2 kDa.

HY-P75054

	*HA/Hemagglutinin Protein, H5N1 (ABR10842, HEK293, His)* Influenza A H5N1 (A/China/2006) Hemagglutinin / HA Protein (HEK293, His)	Virus	HEK293
	The hemagglutinin (HA) protein attaches viral particles to host cells by binding to sialic acid-containing receptors and induces viral particle internalization through clathrin-dependent endocytosis.HA also promotes an alternative clathrin- and caveolin-independent pathway for some virions.HA/Hemagglutinin Protein, H5N1 (ABR10842, HEK293, His) is the recombinant Virus-derived HA/Hemagglutinin protein, expressed by HEK293 , with C-His labeled tag.

HY-P75024

	*HA/Hemagglutinin Protein, H5N9 (ABR37720, sf9, His)* Influenza A H5N9 (A/chicken/Italy/22A/1998) Hemagglutinin / HA Protein (His)	Virus	Sf9 insect cells
	The hemagglutinin HA1 protein is essential for attachment of virions to host cells by binding to sialic acid-containing receptors, inducing virion internalization via clathrin-dependent or clathrin- and caveolin-independent pathways.As a class I viral fusion protein, HA1 determines host range restriction and virulence, mediating fusion between the virion membrane and the endosomal membrane.HA/Hemagglutinin Protein, H5N9 (ABR37720, sf9, His) is the recombinant Virus-derived HA/Hemagglutinin protein, expressed by Sf9 insect cells , with C-His labeled tag.

HY-P74931

	*HA1/Hemagglutinin Protein, H5N9 (ABR37720, HEK293, His)* Influenza A H5N9 (A/chicken/Italy/22A/1998) Hemagglutinin Protein (HA1 Subunit) (His)	Virus	HEK293
	The hemagglutinin HA1 protein is essential for attachment of virions to host cells by binding to sialic acid-containing receptors, inducing virion internalization via clathrin-dependent or clathrin- and caveolin-independent pathways.As a class I viral fusion protein, HA1 determines host range restriction and virulence, mediating fusion between the virion membrane and the endosomal membrane.HA1/Hemagglutinin Protein, H5N9 (ABR37720, HEK293, His) is the recombinant Virus-derived HA1/Hemagglutinin protein, expressed by HEK293 , with C-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-13010S

Laquinimod-d5
Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

Laquinimod-d5

Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

HY-10528S

Tasquinimod-d3
Tasquinimod-d3 (ABR-215050-d3) is the deuterium labeled Tasquinimod (HY-10528). Tasquinimod is an oral antiangiogenic agent, which plays an important role in castration-resistant prostate cancer. Tasquinimod binds to the regulatory Zn ²⁺ binding domain of HDAC4 with K_d of 10-30 nM. Tasquinimod also is a S100A9 inhibitor .

HY-100442S1

Paquinimod-d5-1
Paquinimod-d5-1 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-100442S

Paquinimod-d5
Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

Cat. No.	Product Name		Classification

HY-RS00110

ABR Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
ABR Human Pre-designed siRNA Set A contains three designed siRNAs for ABR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Oligonucleotides